Moderna Inc. said Friday that a booster dose for its COVID-19 vaccine has been authorized by Health Canada for use in people at least 18 years old, at least six months after the completion of the primary two-dose regimen. Last month, U.S. regulators had signed off on extending boosters to Americans who got the Moderna or Johnson & Johnson vaccine, and said eligible people can get a brand different from the shots they originally received. Moderna’s stock fell 1.1% in morning trading. Earlier, the biotechnology company said a Phase 2 trial of its mRNA therapeutic for patients undergoing coronary artery bypass grafting met the primary endpoints of safety and tolerability. Moderna’s stock has tumbled 41.4% over the past three months but has more than doubled (up 119%) year to date, while the S&P 500 has gained 24.9% this year.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
